NCT02770040View on ClinicalTrials.gov

Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis

PHASE4CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

July 18, 2016

Primary Completion Date

October 1, 2021

Study Completion Date

September 7, 2022

Conditions
Ulcerative Colitis
Interventions
DRUG

Infliximab

INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused

Trial Locations (1)

3084

Austin Health, Melbourne

Sponsors

Lead Sponsor

Austin Health
All Listed Sponsors
collaborator

University of Melbourne

OTHER

lead

Austin Health

OTHER_GOV